Evidence map›Paper›PMID 31828731›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2020

Activation of the Protective Arm of the Renin Angiotensin System in Demyelinating Disease.

Roslynn E Stone, Siyu Liu, Alexander M Levy, Nicole Kashani, Stan G Louie, Kathleen E Rodgers, Eve E Kelland, Brett T Lund

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. The Angiotensin ATPharmacological reviews · 2022
    Review
  8. Review
  9. Review
  10. Is serum angiotensin-converting enzyme a suitable biomarker for differentiating idiopathic and demyelinating optic neuritis?Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Roslynn E StoneSchool of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA, 90089, USA.
Siyu LiuSchool of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA, 90089, USA.
Alexander M LevyKeck School of Medicine, Department of Neurology, University of Southern California, 1333 San Pablo Street, Los Angeles, CA, 90033, USA.
Nicole KashaniKeck School of Medicine, Department of Neurology, University of Southern California, 1333 San Pablo Street, Los Angeles, CA, 90033, USA.
Stan G LouieSchool of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA, 90089, USA.
Kathleen E RodgersSchool of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA, 90089, USA.
Eve E KellandKeck School of Medicine, Department of Neurology, University of Southern California, 1333 San Pablo Street, Los Angeles, CA, 90033, USA.
Brett T LundKeck School of Medicine, Department of Neurology, University of Southern California, 1333 San Pablo Street, Los Angeles, CA, 90033, USA. blund@usc.edu.ORCID 0000-0002-4167-2271
University of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The renin angiotensin system (RAS), which is classically known for blood pressure regulation, has functions beyond this. There are two axes of RAS that work to counterbalance each other and are active throughout the body, including the CNS. The pathological axis, consisting of angiotensin II (A1-8), angiotensin converting enzyme (ACE) and the angiotensin II type 1 receptor (AT1R), is upregulated in many CNS diseases, including multiple sclerosis (MS). MS is an autoimmune and neurodegenerative disease of the CNS characterized by inflammation, demyelination and axonal degeneration. Published research has described increased expression of AT1R and ACE in tissues from MS patients and in animal models of MS such as experimental autoimmune encephalomyelitis (EAE). In contrast to the pathological axis, little is known about the protective axes of RAS in MS and EAE. In other neurological conditions the protective axis, which includes A1-7, ACE2, angiotensin II type 2 receptor and Mas receptor, has been shown to have anti-inflammatory, regenerative and neuroprotective effects. Here we show, for the first time, changes in the protective arm of RAS in both EAE and MS CNS tissue. We observed a significant increase in expression of the protective arm during stages of disease stabilization in EAE, and in MS tissue showing evidence of remyelination. These data provide evidence that the protective arm of RAS, through both ligand and receptor expression, is associated with reductions in the pathological processes that occur in the earlier stages of MS and EAE, possibly slowing the neurodegenerative process and enhancing neural repair. Graphical Abstract.

Indexed as

AnimalsBrainCells, CulturedDemyelinating DiseasesEncephalomyelitis, Autoimmune, ExperimentalHumansMaleMiceMice, Inbred C57BLMyelin-Oligodendrocyte GlycoproteinPeptide FragmentsRenin-Angiotensin SystemSpinal CordMyelin-Oligodendrocyte Glycoproteinmyelin oligodendrocyte glycoprotein (35-55)Peptide FragmentsAngiotensin (1–7)Angiotensin II type II receptor (AT2R)Mas receptorMultiple sclerosis (MS)Renin angiotensin system (RAS)

Identifiers

PMID31828731
OpenAlexW2995676135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.